Elemental change in
the neuro-therapeutic landscape

Clene has a new vision for

a pharmaceutical future using

therapeutic nanocatalysts to

improve cellular bioenergetics.

Learn more

Clinical studies

Clene’s clinical program targets neurodegenerative disease to improve cellular bioenergetic function with nanocatalysts. Current Phase 2 studies include treatment of multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease)–neurodegenerative diseases with high unmet medical need. This approach may have broad applications across therapeutic areas with impaired bioenergetics.

About Clene studies

Leadership

Clene has developed an innovative class of medicines utilizing clean surfaced faceted nanocrystals of pure transition elements. Learn more about the leadership team pioneering this novel therapeutic paradigm.

People behind Clene

Elemental change

The convergence of insights from cell biology, solid state physics, and materials science has enabled a breakthrough in nanotechnology therapeutics. Clene has pioneered the development of Clean Surfaced Nanocrystal (CSN)™ therapeutics, opening the possibility of significant clinical benefit in neurodegenerative diseases previously deemed intractable to treatment. For these disorders which are associated with bioenergetic impairment and limited self-repair, CSN™ therapeutics offers unprecedented potential to have a significant benefit for people with these diseases.

Our Technology

Nanocatalysis: A Paradigm
Shift in Therapeutic
Approach

Nanocatalysis is the process of enhancing energetic support in neurons and oligodendrocytes. Nanocatalysis works in stressed cells by enhancing key metabolic reactions by acting as an electron reservoir. By donating and/or receiving electrons as needed, our neuro-therapeutic, CNM-Au8, increases cellular energy reserves, while independently decreasing harmful reactive molecules through direct catalytic activity. Nanocatalysis can improve the survival and function of neurons in addition to supporting oligodendrocytes’ ability to create new myelin.

Our Pipeline